Inspire Pharmaceuticals has nominated Richard Kent, president and CEO of Serenex, to replace President Gregory Mossinghoff on its board of directors..

The board terms for Mossinghoff and Christy Shaffer, chief executive officer of Inspire, expire this year. The board has nominated Shaffer again, but not Mossinghoff, who Kent has agreed to stand in for as a nominee at the company’s annual meeting on June 10.

Inspire says the election of Kent would increase the number of independent directors on its board while maintaining its size of seven members.

Kent is head of Durham-based Serenex, a private drug discovery company specializing in chemoproteomics technology. He has more than 20 years of global pharmaceutical experience, including serving as senior vice president of global medical affairs and chief medical officer for GlaxoSmithKline.

Prior to GSK, Kent held senior positions at Glaxo Wellcome and Burroughs Wellcome, and served on the board of Glaxo. He also was on other senior level operating committees responsible for directing the development and commercialization of products.

“Inspire is fortunate to have a nominee with the extensive experience of Dr. Kent in medicine, pharmaceutical research and development, and management of worldwide scientific and medical services for a major company,” said Leigh Thompson, Inspire’s board chairman. “As we expand the horizon of Inspire to include new therapeutic areas, Dr. Kent’s breadth of expertise will be particularly valuable.”